Search results for "ibi"

showing 10 items of 13473 documents

Current advances in γδ T cell-based tumor immunotherapy

2017

γδ T cells are a minor population (~5%) of CD3 T cells in the peripheral blood, but abound in other anatomic sites such as the intestine or the skin. There are two major subsets of γδ T cells: those that express Vd1 gene, paired with different Vγ elements, abound in the intestine and the skin, and recognize the major histocompatibility complex (MHC) class I-related molecules such as MHC class I-related molecule A, MHC class I-related molecule B, and UL16-binding protein expressed on many stressed and tumor cells. Conversely, γδ T cells expressing the Vδ2 gene paired with the Vγ9 chain are the predominant (50-90%) γδ T cell population in the peripheral blood and recognize phosphoant…

0301 basic medicinelcsh:Immunologic diseases. AllergyAdoptive cell transferadoptive transferT cellImmunologyReviewBiologyMajor histocompatibility complexγδ T cells03 medical and health sciencesInterleukin 210302 clinical medicineAdoptive transfer; Immunoevasion; Immunotherapy; Zoledronate; γδ T cells; Immunology and Allergy; ImmunologyMHC class ImedicineCytotoxic T cellImmunology and AllergyAdoptive transfer Immunoevasion Immunotherapy Zoledronate γδ T cellsGamma delta T cellγδ T cellMHC restriction030104 developmental biologymedicine.anatomical_structureImmunologybiology.proteinimmunoevasionimmunotherapylcsh:RC581-607030215 immunologyZoledronate
researchProduct

Nitration of Wheat Amylase Trypsin Inhibitors Increases Their Innate and Adaptive Immunostimulatory Potential

2018

Amylase trypsin inhibitors (ATI) can be found in all gluten containing cereals and are, therefore, ingredient of basic foods like bread or pasta. In the gut ATI can mediate innate immunity via activation of the Toll-like receptor 4 (TLR4) on immune cells residing in the lamina propria, promoting intestinal, as well as extra-intestinal, inflammation. Inflammatory conditions can induce formation of peroxynitrite (ONOO-) and, thereby, endogenous protein nitration in the body. Moreover, air pollutants like ozone (O3) and nitrogen dioxide (NO2) can cause exogenous protein nitration in the environment. Both reaction pathways may lead to the nitration of ATI. To investigate if and how nitration mo…

0301 basic medicinelcsh:Immunologic diseases. AllergyCell SurvivalT cellnon-celiac wheat sensitivityImmunologyInflammationAdaptive ImmunityImmunophenotyping03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemprotein nitrationT-Lymphocyte SubsetsNitrationCell Line TumorwheatmedicineImmunology and AllergyHumansamylase trypsin inhibitorsTriticumPlant ProteinsOriginal ResearchInnate immune systemMacrophagesfood and beveragesDendritic CellsTetranitromethaneallergyImmunity InnateToll-Like Receptor 4030104 developmental biologymedicine.anatomical_structurechemistryBiochemistryAmylasesTLR4Cytokinesmedicine.symptomlcsh:RC581-607Trypsin InhibitorsPeroxynitriteBiomarkers030215 immunologyFrontiers in immunology
researchProduct

Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells.

2017

ABSTRACT The B16F10 murine melanoma cell line displays a low expression of MHC class I molecules favoring immune evasion and metastases in immunocompetent C57 BL/6 wild-type mice. Here, we generated metastases to the liver, an organ that is skewed towards immune tolerance, by intrasplenic injection of B16F10 cells in syngeneic C57 BL/6 compared to allogeneic Balb/c mice. Surprisingly, Balb/c mice, which usually display a pronounced M2 macrophage and Th2 T cell polarization, were ∼3 times more susceptible to metastasis than C57 BL/6 mice, despite a much higher M1 and Th1 T cell immune response. The anti-metastatic advantage of C57 BL/6 mice could be attributed to a more potent NK-cell mediat…

0301 basic medicinelcsh:Immunologic diseases. AllergyImmunologyNK cellsMajor histocompatibility complexcancer immunologyliverlcsh:RC254-282BALB/cImmune toleranceMetastasis03 medical and health sciencesImmune systemMHC class ImedicineImmunology and Allergymetastasisinnate immunityOriginal ResearchInnate immune systembiologybiology.organism_classificationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmacrophages030104 developmental biologyOncologyCancer cellCancer researchbiology.proteinlcsh:RC581-607Oncoimmunology
researchProduct

TNFSF14 (LIGHT) Exhibits Inflammatory Activities in Lung Fibroblasts Complementary to IL-13 and TGF-β

2018

The cytokine TNFSF14 [homologous to Lymphotoxin, exhibits Inducible expression and competes with HSV Glycoprotein D for binding to HVEM, a receptor expressed on T lymphocytes (LIGHT)] has been shown in mouse models to be important for development of lung tissue remodeling that is characteristic of asthma, idiopathic pulmonary fibrosis (IPF), and systemic sclerosis (SSc). However, its cellular targets are not fully delineated. In the present report, we show that LTβR and HVEM, the receptors for LIGHT, are constitutively expressed in primary human lung fibroblasts (HLFs). We asked whether LIGHT could promote inflammatory and remodeling-relevant activity in HLFs and how this was similar to, or…

0301 basic medicinelcsh:Immunologic diseases. AllergyTGF-βChemokineTumor Necrosis Factor Ligand Superfamily Member 14medicine.medical_treatmentImmunologyGene ExpressionInflammationProinflammatory cytokineCell Line03 medical and health sciences0302 clinical medicineTransforming Growth Factor betamedicineImmunology and AllergyHumansLungCells CulturedOriginal ResearchCell ProliferationInterleukin-13biologyChemistrylung fibroblastsasthmaFibroblasts3. Good healtha receptor expressed on T lymphocytes030104 developmental biologyCytokineLymphotoxinCXCL5030220 oncology & carcinogenesisIL-13Interleukin 13biology.proteinCancer researchCytokinesexhibits Inducible expression and competes with HSV Glycoprotein D for binding to HVEMmedicine.symptomhomologous to LymphotoxinInflammation Mediatorslcsh:RC581-607MyofibroblastBiomarkersFrontiers in Immunology
researchProduct

Harnessing Unconventional T Cells for Immunotherapy of Tuberculosis

2020

Even if the incidence of tuberculosis (TB) has been decreasing over the last years, the number of patients with TB is increasing worldwide. The emergence of multidrug-resistant and extensively drug-resistant TB is making control of TB more difficult. Mycobacterium bovis bacillus Calmette–Guérin vaccine fails to prevent pulmonary TB in adults, and there is an urgent need for a vaccine that is also effective in patients with human immunodeficiency virus (HIV) coinfection. Therefore, TB control may benefit on novel therapeutic options beyond antimicrobial treatment. Host-directed immunotherapies could offer therapeutic strategies for patients with drug-resistant TB or with HIV and TB coinfecti…

0301 basic medicinelcsh:Immunologic diseases. AllergyTuberculosismedicine.medical_treatmentT cellImmunologyCD1HIV InfectionsMajor histocompatibility complexMucosal-Associated Invariant T Cellshost-directed therapy03 medical and health sciences0302 clinical medicineMHC class ImedicineImmunology and AllergyHumansTuberculosis Pulmonarybiologybusiness.industryImmunotherapyMycobacterium tuberculosisDonor Lymphocytesmedicine.diseaseAdoptive Transfer030104 developmental biologymedicine.anatomical_structuretuberculosisImmunologybiology.proteinCoinfectionBCG VaccineHIV-1cytotoxicityT cell receptorbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium diffi…

2016

Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against Clostridium difficile infection (CDI). Standard therapy using antibiotics is associated with a high rate of disease recurrence, highlighting the need for novel treatment strategies that target toxins, the major virulence factors, rather than the organism itself. Human monoclonal antibodies MK-3415A (actoxumab–bezlotoxumab) to C. difficile toxin A and toxin B, as an emerging non-antibiotic approach, significantly reduced the recurrence of CDI in animal models and human clinical trials. Although the main mechanism of protection is through direct neutraliza…

0301 basic medicinelcsh:QR1-502gut microbiomeGut floralcsh:MicrobiologyantibioticsMiceLactobacillusLongitudinal StudiesOriginal Researchbiologyactoxumab and bezlotoxumabMK-3415AAntibodies MonoclonalClostridium difficile3. Good healthAnti-Bacterial AgentsInfectious DiseasesTreatment Outcome16S rDNA amplicon sequencingVancomycinmedicine.drugMicrobiology (medical)030106 microbiologyImmunologyClostridium difficile toxin AColonisation resistanceC. difficile toxin antibodyMicrobiologyMicrobiology03 medical and health sciencesVancomycinClostridium difficile infectionimmune therapymedicineAnimalsClostridioides difficileAkkermansiabiology.organism_classificationAntibodies NeutralizingSurvival AnalysisGastrointestinal MicrobiomeDisease Models Animal030104 developmental biologyBayesian networksBezlotoxumabImmunologyClostridium InfectionsAntitoxinsBroadly Neutralizing AntibodiesFrontiers in Cellular and Infection Microbiology
researchProduct

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

2017

urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies…

0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Natural visibility graphs for diagnosing attention deficit hyperactivity disorder (ADHD)

2016

“NOTICE: this is the author’s version of a work that was accepted for publication in Electronic Notes in Discrete Mathematics. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Electronic Notes in Discrete Mathematics, [Volume 54, October 2016, Pages 337-342] DOI 10.1016/j.endm.2016.09.058 ¨

0301 basic medicinemedia_common.quotation_subjectAttention deficit hyperactivity disorder03 medical and health sciencesDisk formatting0302 clinical medicinemedicineDiscrete Mathematics and CombinatoricsAttention deficit hyperactivity disorderNatural (music)Quality (business)Mathematicsmedia_commonNoticebusiness.industryApplied MathematicsVisibility (geometry)medicine.disease030104 developmental biologyPublishingKolmogorov-Smirnov testbusinessMATEMATICA APLICADANatural visibility graph030217 neurology & neurosurgeryCognitive psychology
researchProduct

A new class of phenylhydrazinylidene derivatives as inhibitors of Staphylococcus aureus biofilm formation

2016

In the struggle against the emergence of the antibiotic resistance, new molecules targeting biofilm formation could be useful as adjuvant of conventional antibiotics. This study focused on a new class of 2-phenylhydrazinylidene derivatives as antivirulence agents. The compound 12e showed interesting activities against biofilm formation of all tested Staphylococcus aureus strains with IC50 ranging from 1.7 to 43 µM; compounds 12f and 13a resulted strong inhibitors of S. aureus ATCC 6538 and ATCC 29213 biofilm formation with IC50 of 0.9 and 0.8 µM, respectively. A preliminary study on the mechanism of action was carried on evaluating the inhibition of sortase A transpeptidase. Compound 12e re…

0301 basic medicinemedicine.drug_class030106 microbiologyAntibioticsBacterial adhesionAntibiofilm agentSettore BIO/19 - Microbiologia Generalemedicine.disease_causeMicrobiologyAntivirulence agent03 medical and health sciencesAntibiotic resistanceIn vivomedicineGeneral Pharmacology Toxicology and PharmaceuticsbiologyChemistrySortase AOrganic ChemistryBiofilmPhenylhydrazinylidene derivativebiochemical phenomena metabolism and nutritionbiology.organism_classificationSettore CHIM/08 - Chimica FarmaceuticaGalleria mellonellaSettore AGR/11 - Entomologia Generale E Applicata030104 developmental biologyMechanism of actionBiochemistryStaphylococcus aureusPharmacology Toxicology and Pharmaceutics (all)Sortase Amedicine.symptomMedicinal Chemistry Research
researchProduct

A Two-Component regulatory system with opposite effects on glycopeptide antibiotic biosynthesis and resistance

2020

AbstractThe glycopeptide A40926, produced by the actinomycete Nonomuraea gerenzanensis, is the precursor of dalbavancin, a second-generation glycopeptide antibiotic approved for clinical use in the USA and Europe in 2014 and 2015, respectively. The final product of the biosynthetic pathway is an O-acetylated form of A40926 (acA40926). Glycopeptide biosynthesis in N. gerenzanensis is dependent upon the dbv gene cluster that encodes, in addition to the two essential positive regulators Dbv3 and Dbv4, the putative members of a two-component signal transduction system, specifically the response regulator Dbv6 and the sensor kinase Dbv22. The aim of this work was to assign a role to these two ge…

0301 basic medicinemedicine.drug_class030106 microbiologylcsh:MedicineGlycopeptide antibioticIndustrial microbiologyArticle03 medical and health sciencesBacterial ProteinsTranscription (biology)Genes RegulatorGene clustermedicinelcsh:ScienceGeneRegulator geneRegulation of gene expressionMultidisciplinaryAntimicrobialsChemistrylcsh:RGene Expression Regulation BacterialGlycopeptideAnti-Bacterial AgentsBiosynthetic PathwaysCell biologyActinobacteriaResponse regulator030104 developmental biologyMultigene FamilyTwo component regulatory system glycopeptide A40926 actinomycete Nonomuraea gerenzanensislcsh:QTeicoplaninMicrobial geneticsScientific Reports
researchProduct